Andover Research Eye Institute
Andover, Massachusetts, 01810, United States
NCT Number: NCT05660681
The primary objective is to evaluate the tolerability and efficacy of CWT-f-002 lubricant eye drops in the treatment of the signs and symptoms of dry eye disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Andover, Massachusetts, 01810, United States
In this study CWT-f-002 lubricant eye drop is being evaluated in subjects with dry eye. This OTC eye drop has previously shown promising results in multiple preclinical and clinical settings. The active comparator for this study is Systane (R). Ingredient lists as follows. CWT-f-002: Active Ingredients are glycerin 0.7% and polyethylene glycol 400 0.4%. Inactive ingredients are mannitol, polylysine-graft-polyethylene glycol, sterile water for injection, and sodium phosphate buffer. Systane: Active ingredients are polyethylene glycol 400 0.4% and propylene glycol 0.3%. Inactive ingredients are boric acid, calcium chloride, hydroxypropyl guar, magnesium chloride, potassium chloride, purified water, sodium chloride, zinc chloride. Systane (R) may contain hydrochloric acid and/or sodium hydroxide to adjust pH. Both products are preservative free and supplied in unit dosers.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eye drop with active agents from the OTC Monograph.
Other names: CWT-f-002
Eye drop with active agents from the OTC Monograph.
Other names: Systane (R)
Time frame: 15 minutes after eye drop instillation
State-of-the-art methodology to assess tear stability.
Calm Water Therapeutics LLC
Industry
A Single-Center, Double-Masked, Randomized Study Evaluating the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops Compared to Systane® Preservative-Free Eye Drops in the Treatment of the Signs and Symptoms of Dry Eye Disease (DED)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07238699
Dry Eye Disease, Dry Eye Syndromes
Sydney, New South Wales, Australia
View Trial DetailsNCT07025811
Dry Eye Disease, Dry Eye Syndromes
Newport Beach, California, United States
View Trial DetailsNCT07128628
Dry Eye Disease, Dry Eye Syndromes
Phoenix, Arizona, United States
View Trial DetailsNCT07264517
Autoimmune Diseases, Dry Eye Disease
Glendale, California, United States
View Trial Details